跳至主要内容
临床试验/NCT02079350
NCT02079350已完成不适用

Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation

Turkiye Yuksek Ihtisas Education and Research Hospital1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
36
试验地点
1
主要终点
renal dysfunction

研究概览

简要总结

Although the negative impacts of colloid solutions with high molecular weight on renal functions, combination of lower molecular weight colloid varieties with crystalloid solutions and its use during intraoperative period have been subject to current research. Since the first liver transplantation, pre-or post-transplantation renal problems are still among the main causes of mortality and morbidity. The aim of the study was to evaluate the effects of fluid replacement solutions used intraoperatively on renal functions in elective living-donor liver transplantation.This study was approved by the Ethics Committee of Hospital and all patients were informed and gave written consent. Participants were patients scheduled for elective living-donor liver transplantation. Patients with normal renal function were randomly allocated to infusion with 6% HES 130/0.4 (HES Group) and 4% Gelofusine (GEL Group). Blood samples were obtained before induction of anesthesia (baseline), at the end of the operation, and postoperative days 1 and 4. Different eGFR formulas using creatinine (MDRD, CKD-EPI, and Cockraud Gault) were used to calculate estimated glomerular filtration rates.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Normal kidney function

排除标准

  • anormal kidney function
  • cadaveric transplantation
  • emergency operation
  • patients less than 18 years old

研究组 & 干预措施

%4 Gelofusine

patients administered %4 Gelofusine during liver transplantation

干预措施: %6 HES and %4 Gelofusine (Drug)

%6 HES

patients administered %6 HES during liver transplantation

干预措施: %6 HES and %4 Gelofusine (Drug)

结局指标

主要结局

renal dysfunction

时间窗: 1 month

次要结局

  • mortality(1 month)

研究者

发起方
Turkiye Yuksek Ihtisas Education and Research Hospital
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

aslı demir

Associated professor

Turkiye Yuksek Ihtisas Education and Research Hospital

研究点 (1)

Loading locations...

相似试验